{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:29:08Z","timestamp":1790242148252,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2013R1A1A2058447"],"award-info":[{"award-number":["NRF-2013R1A1A2058447"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C2449"],"award-info":[{"award-number":["HI14C2449"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00262-016-1830-9","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T06:29:01Z","timestamp":1459405741000},"page":"663-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["2\u2032\u20135\u2032 Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons"],"prefix":"10.1007","volume":"65","author":[{"given":"Chan Kyu","family":"Sim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Sook","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jeoung","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong Sup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,31]]},"reference":[{"issue":"1","key":"1830_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/138161210789941847","volume":"16","author":"A Urruticoechea","year":"2010","unstructured":"Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G (2010) Recent advances in cancer therapy: an overview. Curr Pharm Des 16(1):3\u201310","journal-title":"Curr Pharm Des"},{"issue":"4","key":"1830_CR2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12(4):237\u2013251. doi: 10.1038\/nrc3237","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"1830_CR3","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014\u20131022. doi: 10.1038\/ni.2703","journal-title":"Nat Immunol"},{"issue":"4","key":"1830_CR4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.it.2015.02.006","volume":"36","author":"SB Coffelt","year":"2015","unstructured":"Coffelt SB, de Visser KE (2015) Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol 36(4):198\u2013216. doi: 10.1016\/j.it.2015.02.006","journal-title":"Trends Immunol"},{"key":"1830_CR5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev.biochem.76.060605.122847","volume":"76","author":"MS Lee","year":"2007","unstructured":"Lee MS, Kim YJ (2007) Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 76:447\u2013480. doi: 10.1146\/annurev.biochem.76.060605.122847","journal-title":"Annu Rev Biochem"},{"issue":"7344","key":"1830_CR6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472(7344):481\u2013485. doi: 10.1038\/nature09907","journal-title":"Nature"},{"key":"1830_CR7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","volume":"23","author":"AN Theofilopoulos","year":"2005","unstructured":"Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha\/beta) in immunity and autoimmunity. Annu Rev Immunol 23:307\u2013336. doi: 10.1146\/annurev.immunol.23.021704.115843","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"1830_CR8","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208(10):1989\u20132003. doi: 10.1084\/jem.20101158","journal-title":"J Exp Med"},{"issue":"10","key":"1830_CR9","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","volume":"208","author":"MB Fuertes","year":"2011","unstructured":"Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF (2011) Host type I IFN signals are required for antitumor CD8\u00a0+\u00a0T cell responses through CD8{alpha}\u00a0+\u00a0dendritic cells. J Exp Med 208(10):2005\u20132016. doi: 10.1084\/jem.20101159","journal-title":"J Exp Med"},{"issue":"11","key":"1830_CR10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nm.1887","volume":"14","author":"H Poeck","year":"2008","unstructured":"Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, Schmidt A, Anz D, Bscheider M, Schwerd T, Berking C, Bourquin C, Kalinke U, Kremmer E, Kato H, Akira S, Meyers R, Hacker G, Neuenhahn M, Busch D, Ruland J, Rothenfusser S, Prinz M, Hornung V, Endres S, Tuting T, Hartmann G (2008) 5\u2032-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 14(11):1256\u20131263. doi: 10.1038\/nm.1887","journal-title":"Nat Med"},{"key":"1830_CR11","doi-asserted-by":"crossref","first-page":"e29179","DOI":"10.4161\/onci.29179","volume":"3","author":"F Aranda","year":"2014","unstructured":"Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L (2014) Trial Watch: toll-like receptor agonists in oncological indications. Oncoimmunology 3:e29179. doi: 10.4161\/onci.29179","journal-title":"Oncoimmunology"},{"issue":"5","key":"1830_CR12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR (2014) STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity 41(5):843\u2013852. doi: 10.1016\/j.immuni.2014.10.019","journal-title":"Immunity"},{"issue":"12","key":"1830_CR13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/cgt.2014.60","volume":"21","author":"H Hashimoto","year":"2014","unstructured":"Hashimoto H, Ueda R, Narumi K, Heike Y, Yoshida T, Aoki K (2014) Type I IFN gene delivery suppresses regulatory T cells within tumors. Cancer Gene Ther 21(12):532\u2013541. doi: 10.1038\/cgt.2014.60","journal-title":"Cancer Gene Ther"},{"issue":"42","key":"1830_CR14","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1038\/onc.2013.458","volume":"33","author":"C Xu","year":"2014","unstructured":"Xu C, Lin L, Cao G, Chen Q, Shou P, Huang Y, Han Y, Wang Y, Shi Y (2014) Interferon-alpha-secreting mesenchymal stem cells exert potent antitumor effect in vivo. Oncogene 33(42):5047\u20135052. doi: 10.1038\/onc.2013.458","journal-title":"Oncogene"},{"issue":"1","key":"1830_CR15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ccr.2013.12.004","volume":"25","author":"X Yang","year":"2014","unstructured":"Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX (2014) Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 25(1):37\u201348. doi: 10.1016\/j.ccr.2013.12.004","journal-title":"Cancer Cell"},{"issue":"4","key":"1830_CR16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/ni.2535","volume":"14","author":"MS Lee","year":"2013","unstructured":"Lee MS, Kim B, Oh GT, Kim YJ (2013) OASL1 inhibits translation of the type I interferon-regulating transcription factor IRF7. Nat Immunol 14(4):346\u2013355. doi: 10.1038\/ni.2535","journal-title":"Nat Immunol"},{"issue":"7","key":"1830_CR17","doi-asserted-by":"crossref","first-page":"e1003478","DOI":"10.1371\/journal.ppat.1003478","volume":"9","author":"MS Lee","year":"2013","unstructured":"Lee MS, Park CH, Jeong YH, Kim YJ, Ha SJ (2013) Negative regulation of type I IFN expression by OASL1 permits chronic viral infection and CD8(+) T-cell exhaustion. PLoS Pathog 9(7):e1003478. doi: 10.1371\/journal.ppat.1003478","journal-title":"PLoS Pathog"},{"issue":"1","key":"1830_CR18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1097-0215(19980925)78:1<41::AID-IJC8>3.0.CO;2-X","volume":"78","author":"H Ji","year":"1998","unstructured":"Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC (1998) Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. International journal of cancer Journal international du cancer 78(1):41\u201345","journal-title":"International journal of cancer Journal international du cancer"},{"issue":"2","key":"1830_CR19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1165\/rcmb.2012-0366MA","volume":"49","author":"R Zaynagetdinov","year":"2013","unstructured":"Zaynagetdinov R, Sherrill TP, Kendall PL, Segal BH, Weller KP, Tighe RM, Blackwell TS (2013) Identification of myeloid cell subsets in murine lungs using flow cytometry. Am J Respir Cell Mol Biol 49(2):180\u2013189. doi: 10.1165\/rcmb.2012-0366MA","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"1830_CR20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nri1845","volume":"6","author":"C Reis e Sousa","year":"2006","unstructured":"Reis e Sousa C (2006) Dendritic cells in a mature age. Nat Rev Immunol 6(6):476\u2013483. doi: 10.1038\/nri1845","journal-title":"Nat Rev Immunol"},{"issue":"28","key":"1830_CR21","doi-asserted-by":"crossref","first-page":"10729","DOI":"10.1073\/pnas.0601956103","volume":"103","author":"P Schnorrer","year":"2006","unstructured":"Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, El-Sukkari D, Davey G, Kupresanin F, Li M, Maraskovsky E, Belz GT, Carbone FR, Shortman K, Heath WR, Villadangos JA (2006) The dominant role of CD8\u00a0+\u00a0dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci USA 103(28):10729\u201310734. doi: 10.1073\/pnas.0601956103","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"1830_CR22","doi-asserted-by":"crossref","first-page":"e102709","DOI":"10.1371\/journal.pone.0102709","volume":"9","author":"AM Monjazeb","year":"2014","unstructured":"Monjazeb AM, Tietze JK, Grossenbacher SK, Hsiao HH, Zamora AE, Mirsoian A, Koehn B, Blazar BR, Weiss JM, Wiltrout RH, Sckisel GD, Murphy WJ (2014) Bystander activation and anti-tumor effects of CD8\u00a0+\u00a0T cells following Interleukin-2 based immunotherapy is independent of CD4\u00a0+\u00a0T cell help. PLoS ONE 9(8):e102709. doi: 10.1371\/journal.pone.0102709","journal-title":"PLoS ONE"},{"issue":"2","key":"1830_CR23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.it.2012.10.004","volume":"34","author":"MB Fuertes","year":"2013","unstructured":"Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF (2013) Type I interferon response and innate immune sensing of cancer. Trends Immunol 34(2):67\u201373. doi: 10.1016\/j.it.2012.10.004","journal-title":"Trends Immunol"},{"issue":"4","key":"1830_CR24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.it.2015.02.003","volume":"36","author":"SR Woo","year":"2015","unstructured":"Woo SR, Corrales L, Gajewski TF (2015) The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol 36(4):250\u2013256. doi: 10.1016\/j.it.2015.02.003","journal-title":"Trends Immunol"},{"issue":"5","key":"1830_CR25","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF (2014) STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41(5):830\u2013842. doi: 10.1016\/j.immuni.2014.10.017","journal-title":"Immunity"},{"issue":"7036","key":"1830_CR26","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nature03547","volume":"434","author":"K Honda","year":"2005","unstructured":"Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T (2005) Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434(7036):1035\u20131040. doi: 10.1038\/nature03547","journal-title":"Nature"},{"key":"1830_CR27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fimmu.2012.00014","volume":"3","author":"RA Kroczek","year":"2012","unstructured":"Kroczek RA, Henn V (2012) The Role of XCR1 and its Ligand XCL1 in Antigen Cross-Presentation by Murine and Human Dendritic Cells. Front Immunol 3:14. doi: 10.3389\/fimmu.2012.00014","journal-title":"Front Immunol"},{"issue":"10","key":"1830_CR28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.it.2012.05.007","volume":"33","author":"A Viola","year":"2012","unstructured":"Viola A, Sarukhan A, Bronte V, Molon B (2012) The pros and cons of chemokines in tumor immunology. Trends Immunol 33(10):496\u2013504. doi: 10.1016\/j.it.2012.05.007","journal-title":"Trends Immunol"},{"issue":"12","key":"1830_CR29","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1158\/2326-6066.CIR-14-0160","volume":"2","author":"MT Chow","year":"2014","unstructured":"Chow MT, Luster AD (2014) Chemokines in cancer. Cancer immunology research 2(12):1125\u20131131. doi: 10.1158\/2326-6066.CIR-14-0160","journal-title":"Chemokines in cancer. Cancer immunology research"},{"issue":"9","key":"1830_CR30","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","volume":"17","author":"S Hervas-Stubbs","year":"2011","unstructured":"Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I (2011) Direct effects of type I interferons on cells of the immune system. Clinical cancer research : an official journal of the American Association for Cancer Research 17(9):2619\u20132627. doi: 10.1158\/1078-0432.CCR-10-1114","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"7","key":"1830_CR31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G (2015) Type I interferons in anticancer immunity. Nat Rev Immunol 15(7):405\u2013414. doi: 10.1038\/nri3845","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"1830_CR32","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","volume":"192","author":"JM Haan den","year":"2000","unstructured":"den Haan JM, Lehar SM, Bevan MJ (2000) CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 192(12):1685\u20131696","journal-title":"J Exp Med"},{"key":"1830_CR33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fimmu.2015.00363","volume":"6","author":"E Gutierrez-Martinez","year":"2015","unstructured":"Gutierrez-Martinez E, Planes R, Anselmi G, Reynolds M, Menezes S, Adiko AC, Saveanu L, Guermonprez P (2015) Cross-Presentation of Cell-Associated Antigens by MHC Class I in Dendritic Cell Subsets. Front Immunol 6:363. doi: 10.3389\/fimmu.2015.00363","journal-title":"Front Immunol"},{"issue":"9","key":"1830_CR34","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.4049\/jimmunol.1101717","volume":"187","author":"K Crozat","year":"2011","unstructured":"Crozat K, Tamoutounour S, Vu Manh TP, Fossum E, Luche H, Ardouin L, Guilliams M, Azukizawa H, Bogen B, Malissen B, Henri S, Dalod M (2011) Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8alpha\u00a0+\u00a0type. Journal of immunology 187(9):4411\u20134415. doi: 10.4049\/jimmunol.1101717","journal-title":"Journal of immunology"},{"issue":"9","key":"1830_CR35","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.4049\/jimmunol.1004163","volume":"186","author":"S Lorenzi","year":"2011","unstructured":"Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, Spada M, Belardelli F, Gabriele L, Schiavoni G (2011) Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. Journal of immunology 186(9):5142\u20135150. doi: 10.4049\/jimmunol.1004163","journal-title":"Journal of immunology"},{"issue":"8","key":"1830_CR36","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.4049\/jimmunol.174.8.4465","volume":"174","author":"JM Curtsinger","year":"2005","unstructured":"Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. Journal of immunology 174(8):4465\u20134469","journal-title":"Journal of immunology"},{"issue":"5","key":"1830_CR37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20050821","volume":"202","author":"GA Kolumam","year":"2005","unstructured":"Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202(5):637\u2013650. doi: 10.1084\/jem.20050821","journal-title":"J Exp Med"},{"issue":"6","key":"1830_CR38","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.4049\/jimmunol.176.6.3315","volume":"176","author":"C Havenar-Daughton","year":"2006","unstructured":"Havenar-Daughton C, Kolumam GA, Murali-Krishna K (2006) Cutting Edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. Journal of immunology 176(6):3315\u20133319","journal-title":"Journal of immunology"},{"issue":"4","key":"1830_CR39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2567.2011.03412.x","volume":"132","author":"JP Huber","year":"2011","unstructured":"Huber JP, Farrar JD (2011) Regulation of effector and memory T-cell functions by type I interferon. Immunology 132(4):466\u2013474. doi: 10.1111\/j.1365-2567.2011.03412.x","journal-title":"Immunology"},{"issue":"4","key":"1830_CR40","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.4049\/jimmunol.176.4.2074","volume":"176","author":"A Bon Le","year":"2006","unstructured":"Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF (2006) Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. Journal of immunology 176(4):2074\u20132078","journal-title":"Journal of immunology"},{"issue":"8","key":"1830_CR41","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.4049\/jimmunol.169.8.4279","volume":"169","author":"KB Nguyen","year":"2002","unstructured":"Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, Caligiuri MA, Durbin JE, Biron CA (2002) Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. Journal of immunology 169(8):4279\u20134287","journal-title":"Journal of immunology"},{"issue":"12","key":"1830_CR42","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.4049\/jimmunol.178.12.7540","volume":"178","author":"JB Swann","year":"2007","unstructured":"Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, Hertzog P, Smyth MJ (2007) Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. Journal of immunology 178(12):7540\u20137549","journal-title":"Journal of immunology"},{"issue":"1","key":"1830_CR43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","volume":"6","author":"E Jonasch","year":"2001","unstructured":"Jonasch E, Haluska FG (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6(1):34\u201355","journal-title":"Oncologist"},{"issue":"4","key":"1830_CR44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.micinf.2010.12.007","volume":"13","author":"KH Richards","year":"2011","unstructured":"Richards KH, Macdonald A (2011) Putting the brakes on the anti-viral response: negative regulators of type I interferon (IFN) production. Microbes Infect 13(4):291\u2013302. doi: 10.1016\/j.micinf.2010.12.007","journal-title":"Microbes Infect"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1830-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-016-1830-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1830-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:33:29Z","timestamp":1558701209000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-016-1830-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1007\/s00262-016-1830-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,31]]}}}